Published in Cancer Cell on May 13, 2013
A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors | NCT02442414
Comprehensive molecular characterization of urothelial bladder carcinoma. Nature (2014) 8.48
ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell (2014) 2.44
Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood (2014) 1.81
A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. Naunyn Schmiedebergs Arch Pharmacol (2014) 1.63
Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors. Genome Med (2015) 1.50
Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations. Sci Signal (2014) 1.49
Molecular pathways: HER3 targeted therapy. Clin Cancer Res (2014) 1.41
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol (2015) 1.37
Targeting of erbB3 receptor to overcome resistance in cancer treatment. Mol Cancer (2014) 1.22
Kinases and pseudokinases: lessons from RAF. Mol Cell Biol (2014) 1.10
erbB3 is an active tyrosine kinase capable of homo- and heterointeractions. Mol Cell Biol (2013) 1.02
Cancer-derived mutations in KEAP1 impair NRF2 degradation but not ubiquitination. Cancer Res (2013) 1.01
Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes. Nat Commun (2014) 1.00
Regulation of ERBB3/HER3 signaling in cancer. Oncotarget (2014) 1.00
Integrated genomic and molecular characterization of cervical cancer. Nature (2017) 0.96
Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients. Oncotarget (2015) 0.94
Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors. Cancer Discov (2015) 0.93
EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo. Transl Oncol (2013) 0.92
Proliferation of colorectal cancer is promoted by two signaling transduction expression patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK. PLoS One (2013) 0.91
Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. J Mol Med (Berl) (2014) 0.91
Pan-Cancer Analysis of Mutation Hotspots in Protein Domains. Cell Syst (2015) 0.89
Complex relationship between ligand binding and dimerization in the epidermal growth factor receptor. Cell Rep (2014) 0.88
Examination of HER3 targeting in cancer using monoclonal antibodies. Proc Natl Acad Sci U S A (2015) 0.88
Immunohistochemical analysis of RTKs expression identified HER3 as a prognostic indicator of gastric cancer. Cancer Sci (2014) 0.87
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World J Gastroenterol (2016) 0.87
ERBB3 knockdown induces cell cycle arrest and activation of Bak and Bax-dependent apoptosis in colon cancer cells. Oncotarget (2014) 0.86
Profile of neratinib and its potential in the treatment of breast cancer. Breast Cancer (Dove Med Press) (2015) 0.86
The EGFR-HER2 module: a stem cell approach to understanding a prime target and driver of solid tumors. Oncogene (2015) 0.85
Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface. J Biol Chem (2013) 0.85
Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma. PLoS One (2016) 0.85
Receptor tyrosine kinases with intracellular pseudokinase domains. Biochem Soc Trans (2013) 0.84
Activating ERBB4 mutations in non-small cell lung cancer. Oncogene (2015) 0.84
Functional consequences of somatic mutations in cancer using protein pocket-based prioritization approach. Genome Med (2014) 0.84
Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies. Langenbecks Arch Surg (2015) 0.82
Epidermal growth factor signaling in transformed cells. Int Rev Cell Mol Biol (2014) 0.81
Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodies. PLoS One (2014) 0.81
Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3. Hum Vaccin Immunother (2015) 0.81
Molecular biology of bladder cancer. Hematol Oncol Clin North Am (2015) 0.80
Identification of cellular proteins that interact with human cytomegalovirus immediate-early protein 1 by protein array assay. Viruses (2013) 0.80
Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. Mol Cancer (2014) 0.80
HER3 protein expression in relation to HER2 positivity in patients with primary colorectal cancer: clinical relevance and prognostic value. Virchows Arch (2015) 0.80
HER2 missense mutations have distinct effects on oncogenic signaling and migration. Proc Natl Acad Sci U S A (2015) 0.79
Predicting response to HER2 kinase inhibition. Oncotarget (2015) 0.79
Loss of Trop2 causes ErbB3 activation through a neuregulin-1-dependent mechanism in the mesenchymal subtype of HNSCC. Oncotarget (2014) 0.77
Novel association of DJ-1 with HER3 potentiates HER3 activation and signaling in cancer. Oncotarget (2016) 0.77
ERBB3 Positively Correlates with Intestinal Stem Cell Markers but Marks a Distinct Non Proliferative Cell Population in Colorectal Cancer. PLoS One (2015) 0.77
Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer. Oncotarget (2016) 0.77
Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds. MAbs (2016) 0.77
HER3 over-expression and overall survival in gastrointestinal cancers. Oncotarget (2015) 0.76
Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling. PLoS One (2016) 0.76
Orchestration of ErbB3 signaling through heterointeractions and homointeractions. Mol Biol Cell (2015) 0.76
Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma. Int J Mol Sci (2015) 0.75
ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1). PLoS One (2017) 0.75
A unified model of the hierarchical and stochastic theories of gastric cancer. Br J Cancer (2017) 0.75
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer Metastasis Rev (2016) 0.75
HER3, but Not HER4, Plays an Essential Role in the Clinicopathology and Prognosis of Gastric Cancer: A Meta-Analysis. PLoS One (2016) 0.75
EGF and NRG induce phosphorylation of HER3/ERBB3 by EGFR using distinct oligomeric mechanisms. Proc Natl Acad Sci U S A (2017) 0.75
Effect of Spatial Inhomogeneities on the Membrane Surface on Receptor Dimerization and Signal Initiation. Front Cell Dev Biol (2016) 0.75
Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells. Mol Pharm (2017) 0.75
Oncogenic Ras triggers hyperproliferation and impairs polarized colonic morphogenesis by autocrine ErbB3 signaling. Oncotarget (2016) 0.75
ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas. Oncotarget (2016) 0.75
Cloning and expression analysis of the gastric carcinoma-related gene, ELCOX3. Oncol Lett (2013) 0.75
Genetic variants in ERBB4 is associated with chronic hepatitis B virus infection. Oncotarget (2016) 0.75
Overcoming resistance to HER2 inhibitors through state-specific kinase binding. Nat Chem Biol (2016) 0.75
A germline ERBB3 variant is a candidate for predisposition to erythroid MDS/erythroleukemia. Leukemia (2016) 0.75
The Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor Family. Front Cell Dev Biol (2016) 0.75
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. World J Gastroenterol (2017) 0.75
Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV. MAbs (2017) 0.75
The non-small cell lung cancer EGFR extracellular domain mutation, M277E, is oncogenic and drug-sensitive. Onco Targets Ther (2017) 0.75
MEG2 is regulated by miR-181a-5p and functions as a tumour suppressor gene to suppress the proliferation and migration of gastric cancer cells. Mol Cancer (2017) 0.75
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell (2006) 21.66
Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science (2009) 21.24
Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science (2003) 16.80
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature (2010) 15.63
Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem (2002) 14.34
Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med (2008) 12.68
De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature (2004) 12.41
Diverse somatic mutation patterns and pathway alterations in human cancers. Nature (2010) 10.83
Regulation of cellular metabolism by protein lysine acetylation. Science (2010) 10.55
The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature (2010) 10.04
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol (2005) 9.95
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res (2003) 9.92
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med (2009) 8.55
Systematic generation of high-resolution deletion coverage of the Drosophila melanogaster genome. Nat Genet (2004) 8.24
A paracrine requirement for hedgehog signalling in cancer. Nature (2008) 8.16
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature (2012) 8.13
The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther (2004) 7.82
Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell (2007) 7.60
Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med (2009) 7.23
Cas6 is an endoribonuclease that generates guide RNAs for invader defense in prokaryotes. Genes Dev (2008) 7.09
Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol (2006) 6.82
Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med (2008) 6.82
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell (2004) 6.12
Acetylation of metabolic enzymes coordinates carbon source utilization and metabolic flux. Science (2010) 6.04
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell (2009) 6.02
Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet (2011) 5.68
Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem (2002) 5.63
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol (2010) 5.62
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol (2008) 5.54
A reserve stem cell population in small intestine renders Lgr5-positive cells dispensable. Nature (2011) 5.45
Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science (2009) 5.40
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res (2008) 5.34
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature (2011) 5.32
Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov (2006) 5.30
Functional profiling of a human cytomegalovirus genome. Proc Natl Acad Sci U S A (2003) 5.21
Recurrent R-spondin fusions in colon cancer. Nature (2012) 5.10
An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell (2003) 5.06
Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res (2005) 4.94
Influence of tumour micro-environment heterogeneity on therapeutic response. Nature (2013) 4.78
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med (2015) 4.78
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet (2012) 4.70
Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science (2004) 4.67
Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A (2011) 4.55
Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell (2009) 4.47